Press release

DSM informs market on the completion of the sale of DSM Sinochem Pharmaceuticals to Bain Capital

Heerlen, NL, 31 Oct 2018 16:00 CET

Royal DSM, a global science-based company in Nutrition, Health and Sustainable Living, informs its stakeholders that Bain Capital today has completed the acquisition of DSM Sinochem Pharmaceuticals (DSP), from DSM and Sinochem Group who each held an equity stake of 50%. The transaction was announced on 29 June 2018.

DSM received about €250 million for its equity stake, excluding an earn-out (estimated at around €50m) and transaction costs. DSM anticipates a book profit of about €110 million on the transaction to be recognized in Q4 2018. DSM expects to receive approximately €275 million in cash following closing, including repayment of debt and after transaction costs. 

For more information

Lieke de Jong-Tops

Senior Communications Manager
+31 45 578 2420
media.contacts@dsm.com

Dave Huizing

Vice President Investor Relations
+31 45 578 2864
investor.relations@dsm.com

Lieke de Jong-Tops

Senior Communications Manager
+31 45 578 2420

Dave Huizing

Vice-President Investor Relations
+31 45 578 2864

This site uses cookies to store information on your computer.

Learn more